Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Thomas E. Lew, Rory Bennett, Victor S. Lin, Ashley Whitechurch, Sasanka M. Handunnetti, Paula Marlton, Yandong Shen, Stephen P. Mulligan, Joshua Misha Lewis Casan, Piers Blombery, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Philip A. Thompson, Mary Ann Anderson